<SEC-DOCUMENT>0001140361-23-002025.txt : 20230118
<SEC-HEADER>0001140361-23-002025.hdr.sgml : 20230118
<ACCEPTANCE-DATETIME>20230118172415
ACCESSION NUMBER:		0001140361-23-002025
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230118
DATE AS OF CHANGE:		20230118

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		23535231

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>ny20006859x2_dfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 22.12.1.5105
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <font style="font-family: 'Times New Roman',Times,serif;"></font>
  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center">
  <div>
    <div style="text-align: center; font-weight: bold;"><font style="font-size: 14pt;">UNITED STATES<br>
        SECURITIES AND EXCHANGE COMMISSION</font><br>
      <font style="font-size: 12pt;">Washington, D.C. 20549</font></div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">SCHEDULE 14A<br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center;"><font style="font-weight: bold;">Proxy Statement Pursuant to Section&#160;14(a) of the<br>
        Securities Exchange Act of 1934<br>
      </font><font style="font-family: 'Times New Roman',Times,serif;"><br>
      </font></div>
    <div>Filed by the Registrant&#160;&#160; &#9744;</div>
    <div>Filed by a party other than the Registrant&#160;&#160; &#9746;</div>
    <div>Check the appropriate box:</div>
    <div>&#9744;<font style="font-family: 'Times New Roman',Times,serif;">&#8194;&#8201;&#8201;Preliminary Proxy Statement</font></div>
    <div>&#9744;<font style="font-family: 'Times New Roman',Times,serif;">&#8194;&#8201;&#8201;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></div>
    <div>&#9744;<font style="font-family: 'Times New Roman',Times,serif;">&#8194;&#8201;&#8201;Definitive Proxy Statement</font></div>
    <div>&#9744;<font style="font-family: 'Times New Roman',Times,serif;">&#8194;&#8201;&#8201;Definitive Additional Materials</font></div>
    <div>&#9746;<font style="font-family: 'Times New Roman',Times,serif;">&#8194;&#8201;&#8201;Soliciting Material under &#167; 240.14a-12</font></div>
    <div><font style="font-family: 'Times New Roman',Times,serif;"> <br>
      </font></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">Amarin Corporation plc</div>
    <div>
      <div style="text-align: center;">
        <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">(Name of Registrant as Specified In Its Charter)</div>
      <div style="font-family: 'Times New Roman',Times,serif;"><br>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Catapult Fund LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Hawkeye Fund LP</div>
    <div style="text-align: center; font-weight: bold;">ISP Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Offshore Master Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Master Fund II LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Athena Fund Ltd</div>
    <div style="text-align: center; font-weight: bold;">Atom Master Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Fund GP LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Fund GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Offshore Fund GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Management GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Management LP</div>
    <div style="text-align: center; font-weight: bold;">Alexander J. Denner, Ph.D.</div>
    <div style="text-align: center; font-weight: bold;">Patrice Bonfiglio</div>
    <div style="text-align: center; font-weight: bold;">Paul Cohen, M.D.<br>
      Mark DiPaolo<br>
      Keith L. Horn<br>
      Odysseas Kostas, M.D.</div>
    <div style="text-align: center; font-weight: bold;">Louis Sterling III<br>
      Diane E. Sullivan</div>
    <div>
      <div style="text-align: center;">
        <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">&#160;(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>
      <div style="font-family: 'Times New Roman',Times,serif;"><br>
      </div>
    </div>
    <div>Payment of Filing Fee (Check all boxes that apply):</div>
    <div>&#9746;<font style="font-family: 'Times New Roman',Times,serif;">&#8194;&#8201;&#8201;No fee required</font></div>
    <div>&#9744;<font style="font-family: 'Times New Roman',Times,serif;">&#8194;&#8201;&#8201;Fee paid previously with preliminary materials</font></div>
    <div>&#9744;<font style="font-family: 'Times New Roman',Times,serif;">&#8194;&#8201;&#8201;Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</font></div>
    <div style="font-family: 'Times New Roman',Times,serif;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>This filing contains a press release issued on January 18, 2023 by Sarissa Capital.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <div style="text-align: center; font-size: 14pt;">Sarissa Capital Calls Out Amarin&#8217;s Sham Board Refreshment</div>
      <div style="text-align: center;"> <br>
      </div>
      <div style="text-align: center;">Sarissa puts little faith in Chairman Per Wold-Olsen&#8217;s board refreshment process that resulted in NO SHAREHOLDER </div>
      <div style="text-align: center;">REPRESENTATIVES ON THE BOARD</div>
      <div style="text-align: center;"> <br>
      </div>
      <div style="text-align: center;">Sarissa believes the board&#8217;s refusal to consider shareholder input on the board despite Amarin&#8217;s failures indicates the current board </div>
      <div style="text-align: center;">does not prioritize interests of shareholders</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Greenwich, CT, January 18, 2023 &#8211; Sarissa Capital Management LP (&#8220;Sarissa&#8221;) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN):</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div>In 2022 alone, Amarin stock lost over two-thirds of its value, and shareholders lost over $840 million in equity.* The European launch is behind schedule, reimbursement in Germany (typically one of the largest markets in Europe) appears
        imperiled, and spending mismanagement has weakened the cash coffers. Yet the board has the audacity to state publicly, &#8220;the Company made solid progress in 2022, against its strategic objectives.&#8221; To shareholders, the owners of the company, these
        statements are gravely concerning because they reflect a total lack of understanding of events and the mission of the board and management &#8211; to maximize value for shareholders. To do so, the company must not destroy value.</div>
      <div> <br>
      </div>
      <div>Indeed, Amarin has repeatedly overpromised and underdelivered. Below are three of many examples.</div>
      <div> <br>
      </div>
      <div>
        <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="zdda2698dfab64d439b2c0bbf42c953b2" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; text-align: right;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Vascepa is a great drug with the potential to have a meaningful impact on society. However, since the label expansion for cardiovascular risk reduction, Amarin stock has lost over 90% of its value.<sup style="font-family: Roboto; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="z636c3a6c5f394756a6a5df82e47d605c" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; text-align: right;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Last year, management committed to launching in up to six key European markets and obtain pricing and reimbursement approval in up to eight European markets in 2022. They launched and&#160;secured positive pricing and reimbursement
                  decisions in only five European markets. In addition, despite the novel drug&#8217;s ability to reduce cardiovascular events and its significant potential to reduce a country&#8217;s healthcare costs, Amarin could not secure reimbursement approval in
                  Germany, a historically top revenue generating country for pharmaceuticals in Europe.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="z29b8302be3a94cd29292536f72af6b37" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; text-align: right;">
                <div style="text-align: left;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Amarin&#8217;s slow, reactive responses to changing market dynamics have destroyed significant shareholder capital. An alarming example from 2022 is Amarin&#8217;s slow response to the US launch of a third generic in January 2022 that quickly and
                  meaningfully reduced sales via both price and volume. Instead of having a plan ready to enact immediately in response to the long anticipated generic risk, Amarin waited six months, until June 2022, to announce a major reduction in
                  expenses. In that time, significant shareholder capital &#8211; and additional credibility of management and the board &#8211; were destroyed.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>In June 2022, shareholders loudly expressed their lack of faith in the board and management at the shareholder meeting. Shareholders such as ourselves share the concern, among many concerns, that the current management and board will continue to
        overpromise and underdeliver and destroy shareholder capital, mismanage expenses, run out of money and massively dilute existing shareholders.</div>
      <div> <br>
      </div>
      <div>Characterizing the board&#8217;s interaction with Sarissa as &#8220;in good faith&#8221; is a gross misrepresentation of the facts. The board, led by Chairman Per Wold-Olsen, showed no sense of urgency in interviewing shareholder candidates for the board and took
        fifteen weeks to interview three Sarissa candidates. A few of the directors acknowledged following Chairman Per Wold-Olsen&#8217;s lead and that the time to interview directors was unnecessarily lengthy. His insistence on a lengthy process confused the
        duration with quality of process, and ultimately the board rejected adding any shareholder representatives to the board in favor of their own candidates. Shareholders are the owners of the company with a vested interest in the company&#8217;s success.
        Yet the board is devoid of any shareholder representatives.</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);" noshade="noshade"></div>
      </div>
      <div>Sarissa is Amarin&#8217;s largest shareholder and has a history of creating significant shareholder value in healthcare companies, including those with cardiovascular drugs such as The Medicines Company. We can only conclude that Amarin&#8217;s board does
        not seek real change and instead wants to remain entrenched at the expense of shareholders.</div>
      <div> <br>
      </div>
      <div>As detailed in our previous press release<sup style="font-family: Roboto; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;&#8224;</sup>, Sarissa has submitted notice to Amarin to call a special meeting to remove Chairman Per Wold-Olsen
        from the board and add 7 directors to the board. In accordance with UK law, Amarin has up to 21 days to call the special meeting, which must be held within 28 days of calling the special meeting. We are asking all shareholders to remain engaged and
        voice their opinions by voting at the special meeting.</div>
      <div><br>
      </div>
      <div>Many shareholders have reached out asking us how to vote at the special meeting, and we will provide instructions in the coming weeks and ahead of the meeting.</div>
      <div><br>
      </div>
      <div>*Calculated between Dec 31, 2021, and Dec 30, 2022, Bloomberg</div>
      <div><sup style="font-family: Roboto; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup>Calculated between Dec 13, 2019, and Jan 13, 2023, Bloomberg</div>
      <div><sup style="font-family: Roboto; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;&#8224;</sup>Press release link: <u>https://www.businesswire.com/news/home/20230109005938/en/Sarissa-Capital-Submits-Notice-to-Call-a-Special-Meeting-of-Amarin-Shareholders-to-Add-Directors-and-Remove-Chairman-Per-Wold-Olsen</u></div>
      <br>
      <div style="text-align: center; text-indent: -72pt; margin-left: 72pt;">###</div>
      <div style="text-align: center; text-indent: -72pt; margin-left: 72pt;"> <br>
      </div>
      <div style="text-align: center; font-style: italic;">CERTAIN INFORMATION CONCERNING THE PARTICIPANTS</div>
      <div style="text-align: center; font-style: italic;"> <br>
      </div>
      <div style="text-align: justify;">Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with the other participants named herein (collectively, &#8220;Sarissa&#8221;), intends to file a preliminary proxy statement and accompanying proxy card with the
        Securities and Exchange Commission (&#8220;SEC&#8221;) to be used to solicit votes for the election of its slate of highly-qualified nominees as directors of Amarin Corporation plc (NASDAQ: AMRN) (the &#8220;Company&#8221;), at a special meeting of shareholders of the
        Company. SARISSA STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON
        THE SEC&#8217;S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS&#8217;
        PROXY SOLICITOR, THE IDENTITY AND CONTACT INFORMATION FOR WHICH WILL BE SET FORTH IN THE PROXY STATEMENT THAT WILL BE MADE AVAILABLE TO SHAREHOLDERS.</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);" noshade="noshade"></div>
      </div>
      <div style="text-align: justify;">The participants in the proxy solicitation are anticipated to include Sarissa Capital, Sarissa Capital Offshore Master Fund LP (&#8220;Offshore&#8221;), Sarissa Capital Master Fund II LP (&#8220;Master II&#8221;), Sarissa Capital Athena
        Offshore Fund Ltd (&#8220;Athena&#8221;), Sarissa Capital Catapult Fund LLC (&#8220;Catapult&#8221;), Sarissa Capital Hawkeye Fund LP (&#8220;Hawkeye&#8221;), ISP Fund LP (&#8220;ISP&#8221;), Atom Master Fund LP (&#8220;Atom&#8221;), Sarissa Capital Management GP LLC (&#8220;Management GP&#8221;), Sarissa Capital
        Offshore Fund GP LLC (&#8220;Offshore GP&#8221;), Sarissa Capital Fund GP LP (&#8220;Fund GP LP&#8221;), Sarissa Capital Fund GP LLC (&#8220;Fund GP LLC&#8221;), Dr. Alexander J. Denner, Patrice Bonfiglio, Dr. Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling
        III&#160; and Diane E. Sullivan.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">As of the date hereof and subject to the further explanatory information set forth in this paragraph, funds and other investment vehicles affiliated with Sarissa Capital and Dr. Denner may be deemed to beneficially
        own, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), 25,210,000 ordinary shares, par value 50 pence per share, of the Company (the &#8220;Shares&#8221;), as more fully described below. In addition,
        as of the date hereof, Mr. Sterling may be deemed to separately beneficially own, within the meaning of Rule 13d-3 under the Exchange Act, 117,772 Shares. Given Mr. Sterling&#8217;s beneficial ownership of Shares, he and the funds and other investment
        vehicles affiliated with Sarissa Capital and Dr. Denner may be deemed to have formed a group within the meaning of Rule 13d-5(b) under the Exchange Act. The number of Shares stated herein that may be deemed to be beneficially owned by Mr. Sterling
        does not include Shares that may be deemed to be beneficially owned by such funds and other investment vehicles, and the number of Shares stated herein that may be deemed to be beneficially owned by such funds and other investment vehicles does not
        include Shares that may be deemed to be beneficially owned by Mr. Sterling. Subject to the preceding sentence, as of the date hereof, the number of Shares that may be deemed to be beneficially owned, within the meaning of Rule 13d-3 under the
        Exchange Act, by funds and other investment vehicles affiliated with Sarissa Capital and Dr. Denner is as follows:</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z3fc80c5b2aa7451aa7fcaf5ed92c8d90" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Sarissa Capital</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">25,210,000</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Offshore</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">6,188,100</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Master II</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">342,600</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Athena</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">3,164,000</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Catapult</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">4,298,200</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Hawkeye</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">3,928,800</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">ISP</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">6,663,377</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Atom</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">624,923</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Management GP</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">25,210,000</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Offshore GP</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">9,694,700</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Fund GP LP</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">17,921,700</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Fund GP LLC</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">17,921,700</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify;">Dr. Denner</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">25,210,000</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>
        <div></div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 72pt; vertical-align: top;">Contact:</td>
              <td style="width: auto; vertical-align: top;">
                <div>Jean Puong<br>
                  Sarissa Capital Management LP<br>
                  info@sarissacap.com</div>
              </td>
            </tr>

        </table>
        <div style="text-align: center; text-indent: -72pt; margin-left: 72pt;">&#160;</div>
      </div>
      <div>
        <hr style="height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none;" align="center" noshade="noshade"></div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
